Fendi Pharmaceutical

Fendi Pharmaceutical is a biopharmaceutical company dedicated to developing novel immunotherapy drugs for difficult-to-treat diseases such as cancer and viral infections. The company's proprietary PRODED™ small-molecule immunotherapy drugs utilize the ubiquitin-proteasome pathway to induce the degradation of pathogenic target proteins while activating the immune system through specific peptides of these pathogenic proteins, thereby aiming to cure cancer and viral infectious diseases. Building on traditional protein degraders, Fendi Pharmaceutical has pioneered the integration of protein degradation with immune self-regulation mechanisms and has been the first to apply artificial intelligence (AI) and molecular simulation technologies to the development of small-molecule drugs for novel immunotherapies, with the goal of accelerating the discovery of highly drug-like small-molecule lead compounds and promoting the development of small-molecule drugs for immunotherapy.